Anti-Human UPK1B Recombinant Antibody (5H9) (CAT#: TAB-241CQ)

Figure 1 is a chart depicting the results from a binding assay of chimeric and mouse antibody to UPKl-Fc as determined by ELISA.

The antibodies tested include monoclonal antibodies IGP and 5H9 and their corresponding chimeric antibody.

Figure 2 depict the binding of 1G9 and 5H9 monoclonal antibodies (MAb) to UPK-Ib transfected cells.

Figure 3 is a series of charts depicting the binding of 1G9 and 5H9 monoclonal antibodies to the human transitional cell carcinoma line.

SW780 cells were stained as described elsewhere herein. Cells were stained with either the 1G9 or 5H9 culture supernatants (wide curves) or with a negative control of hybridoma supernatant (thin curves).

Figure 4 showing results from Antibody-Dependent Cellular Cytotoxicity (ADCC) assays.

The ADCC studies were performed using SW780 cells as tumor targets and human peripheral blood mononuclear cells (PBMCs) as effector cells. These assays have been performed using several independent sources of human donor cells at an effectortarget ratio of 70: 1. The wild type chimeric forms of 1G9 and 5H9 were observed to mediate ADCC. The introduction of the enhancing Fc mutant into the human Fc region enhanced killing by 1 G9 dramatically.